Hemodialysis Machine
Baxter Gambro and NXS have a wide range of machines suitable for your every need in the renal dialysis front. The state of the art Renal Intensive Care machine Prismaflex system and the AK96 Dialysis machine are a few of the units that can address your requirements. Baxter Gambro also make a range of self care heamodialysis machines as well as peritoneal dialysis equipment.
Baxter Gambro manufacture and sell all the consumables that are required for efficient dialysis treatment. From Bloodlines to fistula needles, Baxter Gambro also supply dialyzers and dialyzing solutions for accurate and safe patient treatment.
CRRT Dialysis
Baxter’s Continuous Renal Replacement Therapy (CRRT) solutions are designed for critically ill patients with acute kidney injury (AKI), providing continuous, gentle, and effective blood purification. Baxter offers advanced CRRT machines, such as the Prismaflex and PrisMax systems, which deliver customizable therapy options, ensuring optimal fluid and toxin removal while maintaining hemodynamic stability. These systems support various treatment modalities, including CVVH, CVVHD, and CVVHDF, allowing healthcare professionals to tailor treatments based on patient needs. With innovative technology and a focus on patient safety, Baxter’s CRRT solutions help improve outcomes in intensive care settings.
Peritoneal Dialysis
Baxter has been a pioneer in Peritoneal Dialysis (PD) since introducing the first PD solution in 1960, continuously advancing home dialysis solutions to improve patient outcomes. PD allows patients with End-Stage Renal Disease (ESRD) to maintain independence and a better quality of life while offering potentially improved clinical outcomes at a lower cost than hemodialysis. Baxter’s comprehensive PD portfolio includes innovative solutions like Automated Peritoneal Dialysis (APD) with Remote Patient Management (RPM), enabling real-time monitoring to enhance care and reduce hospitalizations. Through its partnership with the nephrology community, Baxter is committed to expanding access to PD and making it the preferred choice for dialysis therapy.